These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38556093)
1. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial. Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093 [TBL] [Abstract][Full Text] [Related]
2. Trial of Roflumilast Cream for Chronic Plaque Psoriasis. Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H; N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113 [TBL] [Abstract][Full Text] [Related]
3. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472 [TBL] [Abstract][Full Text] [Related]
4. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study. Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296 [TBL] [Abstract][Full Text] [Related]
6. A phase I randomized trial to assess the effect on skin infiltrate thickness and tolerability of topical phosphodiesterase inhibitors in the treatment of psoriasis vulgaris using a modified psoriasis plaque test. Snape SD; Wigger-Alberti W; Goehring UM Br J Dermatol; 2016 Sep; 175(3):479-86. PubMed ID: 27038440 [TBL] [Abstract][Full Text] [Related]
7. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis. Smith B; Collier MR; Wu JJ JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326 [No Abstract] [Full Text] [Related]
9. Roflumilast cream (Zoryve) for atopic dermatitis. Med Lett Drugs Ther; 2024 Sep; 66(1711):150-151. PubMed ID: 39250342 [No Abstract] [Full Text] [Related]
10. A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis. Ghani H; Podwojniak A; Tan IJ; Parikh AK; Sanabria B; Rao B Skin Res Technol; 2024 Sep; 30(9):e70041. PubMed ID: 39206797 [TBL] [Abstract][Full Text] [Related]
11. Polymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report. Garg KS; Kircik L; Tjahjono L J Drugs Dermatol; 2024 Aug; 23(8):686-687. PubMed ID: 39093641 [No Abstract] [Full Text] [Related]
12. Effects of oral roflumilast therapy on body weight and cardiometabolic parameters in patients with psoriasis - results from a randomized controlled trial (PSORRO). Gyldenløve M; Sørensen JA; Fage S; Meteran H; Skov L; Zachariae C; Knop FK; Nielsen ML; Egeberg A J Am Acad Dermatol; 2024 Jul; 91(1):64-71. PubMed ID: 38431099 [TBL] [Abstract][Full Text] [Related]
14. Roflumilast 0.3% Cream: a Phosphodiesterase 4 Inhibitor for the Treatment of Chronic Plaque Psoriasis. Nicolas SE; Bear MD; Kanaan AO; Coman OA; Dima L Am J Ther; 2023 Nov-Dec 01; 30(6):e535-e542. PubMed ID: 37921681 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. Thurston AW; Osborne DW; Snyder S; Higham RC; Burnett P; Berk DR Am J Clin Dermatol; 2023 Mar; 24(2):315-324. PubMed ID: 36422852 [TBL] [Abstract][Full Text] [Related]
16. Topical roflumilast for the treatment of psoriasis. Drakos A; Vender R; Torres T Expert Rev Clin Immunol; 2023; 19(9):1053-1062. PubMed ID: 37243575 [TBL] [Abstract][Full Text] [Related]
17. A Review of Topical Roflumilast for the Treatment of Plaque Psoriasis. Pixley JN; Schaetzle T; Feldman SR Ann Pharmacother; 2023 Aug; 57(8):966-969. PubMed ID: 36420929 [TBL] [Abstract][Full Text] [Related]
18. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
19. Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. Watz H; Bagul N; Rabe KF; Rennard S; Alagappan VK; Román J; Facius A; Calverley PM Int J Chron Obstruct Pulmon Dis; 2018; 13():813-822. PubMed ID: 29563781 [TBL] [Abstract][Full Text] [Related]
20. Assessment of the Vehicle for Roflumilast Cream Compared to a Ceramide-Containing Moisturizing Cream in Mild Eczema. Draelos ZD; Higham RC; Osborne DW; Seal MS; Burnett P; Berk DR J Drugs Dermatol; 2024 Oct; 23(10):834-840. PubMed ID: 39361692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]